Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181991 | 0.87 | CYP2D6 (0.50) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL5807082 | 0.83 | TAAR1 (0.67) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL9339241 | 0.83 | CYP1A2 (0.46) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL108087 | 0.82 | TAAR1 (0.77) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL108109 | 0.80 | TAAR1 (0.62) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL529821 | 0.80 | TAAR1 (0.62) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL437991 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL30194501 | 0.79 | CYP3A4 (0.70) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL10533167 | 0.78 | TAAR1 (0.60) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 | |
| SCHEMBL57649 | 0.78 | TAAR1 (0.71) | CYP3A4CYP1A2MAPTTAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| EP-0713483-B1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | EP | claimed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| US-6030985-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | claimed |
| EP-0635508-B1 | TETRAHYDROPYRIDINE DERIVATIVE HAVING SUBSTITUENTS ON THREE RINGS | ASAHI CHEMICAL IND (JP) | 1999-10-06 | — | — | EP | claimed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | claimed |
| US-5621103-A | 3-(SUBSTITUTED METHYLAMINOCARBONYL)-1,2,3,4-TETRAHYDRO-(1)BENZOTHIENO(2,3-C) PYRIDINES; ANXIOLYTIC AGENTS; LEARNING ENHANCEMENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-04-15 | — | — | US | claimed |
| EP-0713483-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | Astra Aktiebolag (SE) | 1996-05-29 | — | — | EP | claimed |
| EP-0471841-B1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 1995-11-02 | — | — | EP | claimed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | claimed |
| EP-0635508-A1 | TETRAHYDROPYRIDINE DERIVATIVE HAVING SUBSTITUENTS ON THREE RINGS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-01-25 | — | — | EP | claimed |
| EP-0471841-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-02-26 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| CN-106459021-B | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-04-07 | — | — | CN | disclosed |
| US-4999378-A | Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0394440-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4288453-A | A-(1-PHENYL-2,2,2-TRIFLUOROETHOXY (OR -ETHYLTHIO))ALKANOIC ACIDS USEFUL AS ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | SCIENCE UNION ET CIE (FR) | 1981-09-08 | — | — | US | disclosed |
| US-3950339-A | SUBSTITUTED-2-(PYRIMIDINYLTHIO)ACETAMIDOXIMES AND ACETONITRILES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | CYP3A4 4138/4885CYP1A2 2732/4885MAPT 135/4885 |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | CYP3A4 4161/4885CYP1A2 4756/4885MAPT 1188/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CYP3A4 4834/4885CYP1A2 4505/4885MAPT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.